Retatrutide (RETA)

Triple agonist targeting GIP, GLP-1, and glucagon receptors. Showing unprecedented weight loss in clinical trials.

Key Data

Research Status

Phase 3 trials

Half-Life

~6 days

Administration

Subcutaneous injection

Typical Dosage

1-12 mg weekly

Mechanism of Action

Activates three receptor systems (GIP, GLP-1, glucagon) for maximum metabolic effects.

Reported Benefits

• Dramatic weight loss (up to 24%)
• Metabolic improvements
• Potential for fatty liver treatment

All information is presented for Research Use Only (RUO). Not medical advice.